KMT2A and leukemia: These findings provide strong evidence that disrupting the interactions between MLL-AF9 and DOT1L by deleting the previously identified minimum targeting module (Δ10; 865–874aa), and via a single point mutation (I867A) effectively inhibits the growth of MLL-AF9-driven leukemia cells.